CD7 is a protein found on the surface of several types of immune cells, and it plays a role in how those cells communicate, activate, and stick to other cells in the body. It sits on T cells, natural killer (NK) cells, and a small fraction of B cells, appearing very early in T cell development and persisting on most mature T cells throughout life. For decades, CD7 was mainly of interest to immunologists studying how T cells get switched on and off. More recently, it has become a high-profile target in cancer therapy, because it marks the surface of cells involved in some of the hardest-to-treat blood cancers. Understanding what CD7 does in healthy immune function, how its presence or absence serves as a diagnostic clue, and why it has become such a promising target for new treatments helps explain its growing importance in medicine.
Where CD7 Shows Up in the Immune System
CD7 is a roughly 40-kilodalton glycoprotein belonging to the immunoglobulin superfamily, a large family of proteins that share a common structural motif and are involved in cell recognition. It appears very early during the development of T cells in the thymus, making it one of the first surface markers a developing T cell displays. After maturation, CD7 remains on the majority of T cells circulating in the blood, as well as on NK cells, the immune system’s rapid-response killers of virus-infected and cancerous cells.1PubMed. Identification of CD7 glycoprotein as an accessory molecule in HIV-1-mediated syncytium formation and cellfree infection A small subpopulation of B cells also carries it, though this is far less studied.
On NK cells specifically, CD7 is expressed at higher levels on freshly isolated cells compared with NK cells that have been activated by immune-stimulating signals like interleukin-2.2PubMed Central. Expression and function of CD7 molecule on human natural killer cells This pattern hints that CD7 may be most relevant during the early stages of an immune response, before cells have ramped up into full activation mode. The fact that CD7 appears so early in T cell development and stays on most mature cells makes it a reliable marker for identifying T-lineage cells in diagnostic lab work, a detail that becomes important in cancer diagnostics.
What CD7 Does in a Healthy Immune System
CD7 acts as a costimulatory receptor, meaning it helps amplify signals that T cells receive through their primary activation pathway. When T cells encounter a threat, they need multiple confirmatory signals before fully committing to an immune response. CD7 provides one of those confirming nudges. Studies have shown that stimulating CD7 on T cells can trigger the release of interleukin-2, a key growth signal that drives T cell multiplication, and can promote cell proliferation even in both CD4+ and CD8+ T cells.3PubMed. CK226: a novel surface molecule involved in human T cell activation
A protein called SECTM1 (also known as K12) has been identified as a binding partner for CD7. SECTM1 can strongly costimulate T cell proliferation and trigger the production of interferon-gamma, a signaling molecule that ramps up immune defenses against infections and tumors.4PubMed Central. K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation The genes for SECTM1 and CD7 sit right next to each other on chromosome 17, suggesting an evolutionary relationship. Interestingly, the mouse version of SECTM1 binds to mouse CD7 but not human CD7, and the human version activates human NK cells by upregulating several activation markers on their surface.5Journal of Biological Chemistry. Identification of CD7 as a Cognate of the Human K12 (SECTM1) Protein
But CD7 signaling is not always a green light for immune activation. When CD7 is cross-linked together with certain antibody receptors on the T cell surface, the result can actually be suppression of T cell proliferation. This inhibition works through a calcium-dependent pathway that blocks interleukin-2 production and prevents T cells from using externally supplied interleukin-2.6Human Immunology. Signal transduction through crosslinking CD7 and IgM-Fc receptors that inhibits T-cell proliferation So CD7 is not a simple on switch; depending on the context and what other signals are present, it can push T cells toward activation or restraint.
How CD7 Sends Signals Inside the Cell
When CD7 is engaged on a T cell’s surface, it triggers a signaling enzyme called phosphatidylinositol 3-kinase, commonly abbreviated PI3K. This enzyme is a central player in many cellular decisions, from growth to survival to movement. CD7 activates PI3K through a specific sequence of amino acids in its tail that sticks into the cell’s interior. When that motif gets tagged with a phosphate group, PI3K docks onto it and starts producing lipid signals that rearrange the cell’s internal machinery.7The Journal of Immunology. CD7-mediated regulation of integrin adhesiveness on human T cells involves tyrosine phosphorylation-dependent activation of phosphatidylinositol 3-kinase
One practical outcome of this signaling is a change in how sticky the T cell becomes. CD7 activation boosts the function of integrins, which are surface molecules that allow immune cells to grab onto other cells and onto tissue surfaces. This is critical for T cells that need to migrate out of the bloodstream and into infected or damaged tissue. Blocking PI3K with chemical inhibitors shuts down CD7’s ability to increase integrin stickiness, confirming that the PI3K pathway is the actual mechanism at work.7The Journal of Immunology. CD7-mediated regulation of integrin adhesiveness on human T cells involves tyrosine phosphorylation-dependent activation of phosphatidylinositol 3-kinase This signaling pathway shares features with the costimulatory signals sent through CD28, one of the best-known T cell activation molecules, suggesting CD7 may operate as a parallel or complementary costimulatory circuit.8PubMed. Antibody ligation of CD7 leads to association with phosphoinositide 3-kinase and phosphatidylinositol 3,4,5-trisphosphate formation in T lymphocytes
Losing CD7 With Age
Not all T cells keep CD7 on their surface forever. A subset of T cells that have lost CD7 expression, called CD7-negative T cells, accumulates steadily as people age. In cord blood from newborns, essentially no CD7-negative T cells can be detected. After birth, both the percentage and absolute number of these cells climb with each passing decade.9PubMed Central. Progressive increase of CD7- T cells in human blood lymphocytes with ageing Most of these CD7-negative cells are CD4+ helper T cells with a memory phenotype, meaning they have already encountered and responded to a pathogen at some point in the past.10PubMed. CD4+ CD7- T cells: a separate subpopulation of memory T cells?
Research characterizing these cells in detail has found that CD7-negative T cells represent a late stage of memory T cell development. They carry shorter telomeres (the protective caps on chromosome ends that shorten with each cell division), lower levels of the enzyme telomerase, and higher levels of a marker called KLRG-1 that is associated with replicative exhaustion. In the lab, naive CD7-positive T cells can be driven to lose CD7 expression through repeated rounds of stimulation, and once the switch happens, it does not reverse. These aging T cells have a high threshold for activation, diminished ability to carry out immune functions, and increased susceptibility to a form of programmed cell death triggered by activation. The process appears to be a one-way street reflecting accumulated immune wear and tear over a lifetime.
CD7 as a Diagnostic Marker in Blood Cancers
Because CD7 is normally found on almost all T cells, its presence or absence can be a powerful diagnostic clue in blood cancers. In T-cell acute lymphoblastic leukemia (T-ALL), CD7 is typically expressed at high levels on the malignant cells. Researchers have found that sorting leukemia samples by both CD7 and CD34 (a marker of immature blood cells) can distinguish between normal stem cells and the cells that actually drive the leukemia. In those studies, the leukemia-initiating cells were found almost exclusively in the CD7-positive fraction, while CD34-positive cells that lacked CD7 turned out to be normal progenitors capable of producing healthy blood cells.11PubMed. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations
On the flip side, the loss of CD7 from T cells can signal a different category of cancer. In Sézary syndrome and mycosis fungoides, two related forms of cutaneous T-cell lymphoma (cancers of skin-homing T cells), the malignant cells characteristically lack CD7 even though they still express other T cell markers like CD3 and CD4.12PubMed Central. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping Pathologists use this CD7-negative pattern as part of a diagnostic panel to identify these lymphomas, because normal T cells in the skin would be expected to carry CD7. Its absence is a red flag.
CD7 also shows up in unexpected places. In some cases of acute myeloid leukemia (AML), a cancer of a completely different cell lineage, the malignant myeloid cells aberrantly express CD7. Clinicians have noticed that this aberrant expression is closely linked to a specific genetic mutation called FLT3/ITD, which is associated with higher white blood cell counts, more immature-looking cancer cells, and generally worse outcomes.13PubMed. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation Some clinicians view CD7 expression on AML cells as a warning sign that the patient may be less responsive to standard chemotherapy and may have shorter survival times.14PubMed Central. The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients
CD7 in Viral Infections
The behavior of CD7 during chronic viral infections provides another window into its biological significance. In HIV-1 infection, CD8+ T cells show a pronounced loss of CD7 expression compared with healthy people. Both “CD7-low” and “CD7-negative” subsets of CD8+ effector T cells expand dramatically, and the degree of CD7 loss tracks directly with how much virus is circulating in the blood. Patients with rapid disease progression show the most striking depletion of CD7-high cells. Encouragingly, antiretroviral treatment that suppresses viral load partially reverses this shift.15PubMed. Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment This makes CD7 expression on CD8+ T cells a rough gauge of how hard the immune system is being driven by the virus.
A different virus, HTLV-1 (the cause of adult T-cell leukemia/lymphoma), uses CD7 loss as part of its playbook for malignant transformation. Researchers tracking HTLV-1-infected cells found that the virus-carrying cells that are actively expanding in the body tend to cluster in populations that have progressively lost CD7. In people who carry HTLV-1 without symptoms, clonally expanding cells first appear in a population with dimmed but still present CD7. As the disease progresses toward full-blown leukemia, those cells shift into a fully CD7-negative state.16PubMed. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma Tracking CD7 levels on HTLV-1-infected cells could therefore serve as an early warning system for disease progression, potentially flagging patients who need closer monitoring or earlier intervention.
Lessons From Mice That Lack CD7
To understand what CD7 does at the whole-organism level, researchers created mice whose CD7 gene was deliberately knocked out. The surprise was how normal these animals appeared. Their thymuses and spleens looked fine under the microscope. Their lymphocyte populations in both primary and secondary immune tissues were within normal ranges. They produced normal levels of antibodies. Their T cells responded normally to stimulation, and their NK cells killed targets just as effectively as those of normal mice.17PubMed. Targeted gene disruption of murine CD7
But digging deeper revealed subtler abnormalities. CD7-deficient mice had reduced interferon-gamma production in response to specific antigens and showed impaired generation of cytotoxic CD8+ T cells, the cells responsible for killing virus-infected or cancerous cells. They also had significantly fewer NKT cells in the liver, a specialized immune cell population that bridges the innate and adaptive immune systems. These liver NKT cells are thought to play a role in inflammatory shock responses, and sure enough, CD7-knockout mice were strikingly resistant to endotoxin-induced shock, a model of the severe inflammatory crash that can occur during bacterial sepsis.18PubMed Central. Resistance of CD7-deficient mice to lipopolysaccharide-induced shock syndromes This is a fascinating finding because it suggests that CD7, through its role in NKT cell biology, may contribute to the runaway inflammation that makes septic shock so dangerous.
CD7 as a Target for CAR-T Therapy
The feature that has thrust CD7 into the spotlight of modern medicine is its potential as a therapeutic target. T-cell cancers have historically been much harder to treat with immunotherapy than B-cell cancers, in part because the immune cells you would use to attack the cancer (T cells) carry the same surface markers as the cancer cells. CAR-T therapy, which engineers a patient’s T cells to recognize and kill cancer cells bearing a specific target, has been transformative for B-cell cancers by targeting a marker called CD19. But targeting a T-cell marker with T cells creates an obvious problem: the therapeutic cells attack each other. This self-destruction is called fratricide.
CD7 became an appealing target because it is broadly expressed on T-ALL cells and on some AML cells, but the fratricide problem had to be solved first.19PubMed Central. CD7 CAR-T therapy: current developments, improvements, and dilemmas Researchers developed several clever workarounds. One approach uses CRISPR gene editing to delete the CD7 gene from the therapeutic T cells before arming them with the anti-CD7 CAR. Without CD7 on their own surface, these edited T cells can expand normally without killing each other, and their ability to destroy cancer cells remains intact.20PubMed Central. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
A different strategy uses what is called a protein expression blocker, or PEBL. Instead of editing the gene out entirely, this method traps the CD7 protein inside the cell so it never reaches the surface. Transducing T cells with the anti-CD7 PEBL resulted in near-complete loss of surface CD7, dropping expression from about 98% in untreated cells to about 2% in treated cells.21PubMed Central. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies A clinical case series of 17 patients with T-ALL who received autologous CAR-T cells armed with both an anti-CD7 CAR and the PEBL has been reported, demonstrating that this approach can work in actual patients, not just in the lab.22PubMed. Fratricide-resistant CD7-CAR T cells in T-ALL
Taking the concept further, researchers have developed “off-the-shelf” universal CAR-T cells (UCART7) by deleting both CD7 and the T cell receptor alpha chain using multiplex CRISPR editing. Removing the T cell receptor prevents the therapeutic cells from attacking the recipient’s normal tissues, a complication called graft-versus-host disease. In lab studies, these double-knockout cells were as effective at killing T-ALL cell lines as cells with only the CD7 deletion.23PubMed Central. An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies The appeal of a universal product is enormous: it could be manufactured in bulk from donor cells and given to any patient without needing to custom-engineer each patient’s own cells, saving critical time for people with aggressive cancers.
Other Therapeutic Approaches Targeting CD7
CAR-T cells are not the only way to exploit CD7 therapeutically. Antibody-drug conjugates (ADCs) represent another strategy. These are antibodies designed to latch onto CD7 on a cancer cell’s surface and deliver a toxic payload directly into the cell. Preclinical data show that CD7-targeting ADCs with intracellular drug-release properties can selectively kill CD7-positive cells, suggesting they could become a useful treatment for T-ALL, refractory CD7-positive leukemias, and even the subset of AML cases that aberrantly express CD7.24PubMed Central. An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells
CD7 has also been targeted alongside CD3 using immunotoxins, not for cancer, but for graft-versus-host disease (GVHD). GVHD occurs when donated immune cells in a bone marrow transplant attack the recipient’s body. In a phase I/II trial, a combination of anti-CD3 and anti-CD7 immunotoxins was given to 20 patients with steroid-refractory acute GVHD, a severe form that does not respond to standard treatment. Half the patients achieved a complete response by day 28, and six-month overall survival was 60%. The treatment caused a profound but temporary depletion of T cells and NK cells, followed by rapid immune recovery with a diverse repertoire of T cell receptors, and it preserved pre-existing immunity against common viruses like Epstein-Barr virus and cytomegalovirus.25PubMed Central. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease The fact that immunity bounced back so quickly after targeting CD7-bearing cells is consistent with the knockout mouse data showing that loss of CD7 does not cripple the immune system, a reassuring sign for any therapy that temporarily wipes out CD7-positive cells.
Why CD7 Loss Might Not Be Catastrophic
A natural concern with any therapy that eliminates CD7-positive cells is whether the patient would be left dangerously immunocompromised. After all, if CD7 sits on most T cells and NK cells, wouldn’t depleting all those cells leave a person wide open to infections? The mouse knockout studies provide some reassurance on this point. Mice completely lacking CD7 from birth developed normally and handled most immune challenges without trouble. Their most notable vulnerability was in certain specialized responses like cytotoxic T cell generation and interferon-gamma production, rather than a wholesale collapse of immunity.17PubMed. Targeted gene disruption of murine CD7
In human patients treated with CD3/CD7 immunotoxins for GVHD, the transient depletion of T and NK cells was followed by recovery of a diverse immune system within weeks.25PubMed Central. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease The natural accumulation of CD7-negative memory T cells with aging also suggests that a sizable fraction of the mature T cell compartment can function without CD7 on its surface. Whether long-term CD7-targeted therapy would expose patients to specific infectious risks, particularly involving the liver NKT cell deficiencies seen in knockout mice, remains an open question that clinical trials will need to answer over time. For now, the early signals are that CD7-targeted treatments carry a manageable safety profile, which is a large part of why the field has moved so aggressively toward bringing these therapies into the clinic.